cyrilzakka/clinical-trials huggingface dataset:
Objective Assessment of Physical Activity in Before-school Physical Activity Programs

This study will determine the effectiveness of a free before-school physical activity program, BOKS (Build Our Kids' Success), in increasing objectively measured physical activity levels among children in elementary and middle school in 7 schools in Massachusetts.

This study will determine the effectiveness of a free before-school physical activity program, BOKS (Build Our Kids' Success), in increasing objectively measured physical activity levels among children in elementary and middle school in 7 schools in Massachusetts. The study focuses on capturing valid and objective assessments of student-level physical activity during BOKS program time and assessing the impact of the BOKS program on overall daily physical activity levels using minute-by-minute physical activity level data among elementary aged students. Data is also collected to understand how increasing physical activity may impact students' sleep.

Eligibility Criteria:
Inclusion Criteria:

* Attending public elementary and middle school in two selected Massachusetts communities with BOKS programming

Exclusion Criteria:

* None
Influenza Vaccine Postpartum Questionnaire

The purpose of this trial is to assess the knowledge and attitudes of post-partum women regarding influenza and the use of the influenza vaccine in pregnancy.

Women on our post-partum floor will be approached to complete a questionnaire which will assess their knowledge and attitudes regarding influenza and the use of the influenza vaccine in pregnancy. The study will take place over a 2-month period during influenza season, and at the time when the influenza vaccine becomes available.

Eligibility Criteria:
Inclusion Criteria:

* women admitted to the postpartum floor during the study period

Exclusion Criteria:

* inability to read or understand English
DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)

Prospective Internet-Registry, Postmarketing-Surveillance, Registration and Follow-up of patients after Multi-Link VISION™ - Stent Implantation

A Non-Randomized prospective evaluation of the Multi-Link Rx Vision TM Coronary Stent System in the treatment of patients with De novo native coronary artery lesions

Eligibility Criteria:
Inclusion Criteria:

* Women and Men Age \>18 years, Intention to treat all stenosis with Multi-Link VisionTM Stents, documented patient consent

Exclusion Criteria:

* No Multi-Link Vision™ Stent implanted, life expectation \>9 M, cardiogenic shock, STEMI, NSTEMI or unstable angina pectoris with pathologic markers within the last 48 hours, intolerance of Clopidogrel/ Tiklopidin
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a combination of fosamprenavir (increased dose)/lopinavir/ritonavir.


Eligibility Criteria:
Inclusion criteria:

* Multiple protease-inhibitors experienced HIV-1 infected individuals experiencing virological failure and who's virus is not fully resistant to boosted fosamprenavir and boosted lopinavir based on genotypic resistance tests.

Exclusion criteria:

* No full resistance to FPV/r or LPV/r
* Planned use of NNRTIs as part of the study salvage regimen
* Application of additional exclusion criteria as determined by physician.
High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment

Amoxicillin and metronidazole （400mg Q.D.S） based quadruple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the amoxicillin and metronidazole (400mg thrice a day) based triple therapy and the addition of bismuth in the naive patients with helicobacter pylori infection.


Eligibility Criteria:
Inclusion Criteria:

* Participants with non-ulcer functional dyspepsia or peptic ulcer disease
* Ability and willingness to participate in the study and to sign and give informed consent
* Confirmed H. pylori infection and with no previous treatment experience

Exclusion Criteria:

* Less than 18 years old
* With previous gastric surgery
* Major systemic diseases
* Pregnancy or lactation
* Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Investigation of Stent-grafts in Aortic Dissection (INSTEAD)

The objective of INSTEAD is to compare long-term (5 years) outcomes of endograft prosthesis versus medical management in patients with dissection of the thoracic aorta.

Patients \> 18 years with type B aortic dissection were randomized to either thoracic aortic endoprosthesis (stent-grafting) or antihypertensive management (medical treatment). Only stable patients without spontaneous false lumen thrombosis 14 days after index dissection were considered eligible for study inclusion. Long-term outcome measures included all-cause mortality, aorta-specific mortality and a cluster endpoint (reflecting progression of disease, conversion and additional interventions); the analysis is based on 140 randomized cases followed for at least 5 years.

Eligibility Criteria:
Inclusion Criteria:

* No contraindication the general anesthesia and ventilation
* Type B aortic dissection that occurred 2-52 weeks prior to randomization
* Diameter of the targeted aortic segment \< 6 cm
* Subject or legal guardian understand the nature of teh study and agrees to its provisions on a written informed consent form
* Availability for appropriate follow-up visits during the F/U period of 5 years
* Capability to follow all study requirements

Exclusion Criteria:

* Pregnancy
* Thrombocytopenia
* Ongoing anticoagulation therapy
* Renal failure and/or creatinine \> 2,4 mg%
* Complete thrombosis of false lumen
* Cancer likely to cause death within 1 year
* Enrollment in another clinical study
* Unwillingness to cooperate with study procedures or F/U visits
Discover In-Hospital Cardiac Arrest

The Discover In-Hospital Cardiac Arrest (IHCA) study is a multicenter, prospective observational study aimed at better understanding variations in practice for the post-in-hospital cardiac arrest patient.

There is considerable debate among experts concerning many components of intra- and post-arrest care. This study aims to increase the evidence base of these components, particularly temperature control, and prognostication in post-in-hospital cardiac arrest patients. In addition to providing insights regarding immediate and long-term post-arrest care, data collected will also be useful in studying variations in cardiopulmonary resuscitation practices.

This project is endorsed by the Society of Critical Care Medicine's (SCCM) Discovery, the Critical Care Research Network.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥18 years old) patients
* Patients with a cardiac arrest (a lack of palpable pulse or perfusing cardiac activity) while admitted to the hospital
* Patients admitted to a ward (telemetry or non-telemetry) or an intensive care unit, or are admitted but still in the emergency department waiting for a hospital bed
* Patients who achieved return of spontaneous circulation (ROSC defined as \>20 minutes of sustained spontaneous circulation) OR initiated on extracorporeal membrane oxygenation (eCPR) with chest compressions ongoing
* Patients survived for 6 hours after ROSC

Exclusion Criteria:

* Cardiac arrest in non-inpatients (e.g. outpatients, visitors)
* Patients whose cardiopulmonary resuscitation (CPR) starts outside of the hospital
* Non-index arrests (arrests that are not the patient's first arrest during the hospital admission; this also excludes patients who were initially admitted for an out-of-hospital cardiac arrest)
* Patients suffering IHCA in the operating room (OR) or post anesthesia care unit (PACU)
* Patients with cardiac arrest after arriving to an emergency department (ED) but prior to being evaluated and admitted to the hospital
* Cardiac arrests lasting \<2 minutes (i.e. chest compressions performed \<2 minutes)
* Cardiac arrests where the patient is transitioned to comfort focused care within 6 hours of return of spontaneous circulation (ROSC)
Clinical Outcome Study for the Triathlon Cruciate Retaining (CR) Total Knee

An open label, post-market, non-randomised, historical controlled, multi-centre study of the outcomes of the Triathlon Cruciate Retaining (CR) Total Knee System.

An open label, post-market, non-randomised, historical controlled, multi-centre study of the outcomes of the Triathlon Cruciate Retaining (CR) Total Knee System. The primary objective of this study will be to compare the active range of motion values for the Triathlon CR Total Knee System with those of the Scorpio CR Total Knee System, a historical control group. ROM values will be measured by use of a Goniometer according to the protocol. It is expected that the Triathlon CR Total Knee System group's range of motion is not 5 degrees worse or superior to the control group's range of motion at two-years.

Eligibility Criteria:
Inclusion Criteria:

1. Patients willing to sign the Ethic Commission approved, study specific Informed Patient Consent Form.
2. Patients willing and able to comply with scheduled postoperative clinical and radiographic evaluations and rehabilitation.
3. Male or non-pregnant female between the ages of 21-80 years of age at the time of surgery.
4. Patients requiring a primary total knee replacement.
5. Patients with a diagnosis of osteoarthritis (OA), traumatic arthritis (TA), or avascular necrosis (AVN).
6. Patients with intact collateral ligaments.

Exclusion Criteria:

1. Patients with inflammatory arthritis.
2. Patients that are morbidly obese, body mass index (BMI) \> 40.
3. Patients with a history of total / unicompartmental reconstruction of the affected joint.
4. Patients that have had a high tibial osteotomy or femoral osteotomy.
5. Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.
6. Patients with a systemic or metabolic disorder leading to progressive bone deterioration.
7. Patients that are immunologically compromised, or receiving chronic steroids (\>30 days duration).
8. Patients bone stock is compromised by disease or infection which cannot provide adequate support and/or fixation to the prosthesis.
9. Patients with a knee fusion to the affected joint.
10. Patients with an active or suspected latent infection in or about the knee joint.
11. Patients with a history of total joint replacement on the opposite knee within less than 1 year.
12. Patients requiring bilateral total knee replacement.
Effects of Ultrasound-guided Genicular Nerve Block in Knee Osteoarthritis Patients on Proprioception and Static Balance

Genicular nerve block (GNB) is a novel and promising interventional method for pain in knee osteoarthritis (KOA). However ,it contains afferent fibers that receive impulses from proprioceptive and deep sensory receptors located in the joint capsule, ligaments, muscles, tendons and periosteum. These proprioceptive stimuli are effective on joint position and biomechanics, protect the joint from injuries and help maintain balance. This study aims to evaluate Pproprioception and static balance after ultrasound-guided GNB in patients with knee osteoarthritis.

Genicular nerve block (GNB) is a novel and promising interventional method for pain in knee osteoarthritis (KOA). However ,it contains afferent fibers that receive impulses from proprioceptive and deep sensory receptors located in the joint capsule, ligaments, muscles, tendons and periosteum. These proprioceptive stimuli are effective on joint position and biomechanics, protect the joint from injuries and help maintain balance. This study aims to evaluate Pproprioception and static balance after ultrasound-guided GNB in patients with knee osteoarthritis.

Eligibility Criteria:
Inclusion Criteria:

* Chronic knee pain more than \>3 according to visual analog scale (VAS) and difficulty in function more than 3 months
* Grade 2-3 KOA according to the Kellgren -Lawrence radiological grading system
* No significant improvement in response to conservative treatments such as analgesics and physiotherapy.

Exclusion Criteria:

* History of trauma, fractures, malignencies, surgery and inflammatory diseases of knee
* Limitation of range of motion in unilaterally and/or bilaterally in knee joint
* Allergies of pharmacological agents using during procedure (lidocaine)
* Presence of intra-articular or peri-articular injection such as hyaluronic acids, corticosteroids or collagen supplements at last 6 months
* Other neurologic or rheumatological conditions that may lead vertigo or vestibular disfunction or presence of impairment in proprioception such as polineuropathy
* Presence of diabetes mellitus due to risk of small fiber neuropathy
* Cognitive impairment and uncontrolled systemic conditions.
Comparison of Patient-controlled Analgesia Regimenfor Postoperative Pain in Patients Undergoing Total Knee Arthroplasty

Patients who undergoing total knee arthroplasty under spinal analgesia will be recruited and randomly assigned to the following two groups according to the regimen of PCA: (A) opioid group who receive only fentanyl citrate 1200mcg for continuous infusion drug, (B) non-opioid group who receive ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug. All the patients will receive additional fentanyl citrate as bolus injection drug if they need more analgesics postoperatively.


Eligibility Criteria:
Inclusion Criteria:

* ASA physical status I-II
* undergoing elective total knee arthroplasty under spinal anesthesia

Exclusion Criteria:

* history of stomack ulceration
* increased ICP
* bronchial asthma
* allergy on aspirin, NSAIDs, Nefopam
* drug user of antiplatelet or anticoagulant
Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy

The purpose of this study is to assess the effectiveness and acceptability of a recently created informative video geared for patients who have been evaluated by a radiation oncologist for palliative radiation therapy during a hospitalization at Memorial Sloan-Kettering Cancer Center. Palliative radiation therapy is radiation therapy that is given to patients with the purpose of easing symptoms from cancer. It is not given with the intent to cure the cancer. The video presents basic information about palliative radiation and palliative care.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Eligible for palliative radiation to the brain, spine, chest, abdomen, pelvis, skin, or bone as per the judgment of the radiation oncologist or nurse practitioner
* Patient is English-speaking and able to give informed consent and fill out study questionnaires
* Hospitalized at MSKCC
* Pathologically confirmed malignancy
* Cancer is metastatic or locally advanced, and is not curable
* Patients who may undergo radiation at a satellite facility are still eligible for protocol enrollment

Exclusion Criteria:

* Those who have seen the video beforehand
Neuromodulation to Facilitate the Effect of Ketamine

application of external neuromodulation along with ketamine infusion.

apply TMS concurrent with ketamine infusion in order to increase the likliehood \& strength of therapeutic benefit

Eligibility Criteria:
Inclusion Criteria:

* chronically ill,
* treatment-resistant

Exclusion Criteria:

* active psychosis
Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

This single and multiple ascending dose study is the first evaluation of PF-0626414, a Selective Androgen Receptor Modulator in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy western and Japanese male subjects .


Eligibility Criteria:
Inclusion Criteria:

* Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
* Additional inclusion criteria for subjects to be enrolled in Japanese cohort only: Japanese subjects who have four Japanese grandparents born in Japan.

Exclusion Criteria:

* Serum total testosterone level \<270 or \>1070 ng/dL
* Serum Prostate Specific Antigen (PSA) level \>4 ng/mL.
* Hematocrit \>48%.
* eGFR \>150 ml/min/1.73m2.
Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses

This study expands upon pilot data for feasibility since May 2011. The study aims to evaluate the effect of rapid test availability on use of targeted spectrum antibiotics for non-MRSA abscesses in ambulatory patients in the Emergency Department (ED). The multi-institutional study will assess the feasibility of providing the GeneXpert® MRSA/SA SSTI assay to the ED and evaluate the impact of delivering the test result to clinicians in real-time on patient management decisions regarding the use of antimicrobial agents. Patients are randomized to standard culture (control arm) or to the GeneXpert® assay plus standard culture.

Our objective was to determine whether real-time availability of rapid molecular results of Staphylococcus aureus would impact emergency department clinician antimicrobial selection for adults with cutaneous abscesses.

We performed a prospective, randomized controlled trial in two urban emergency departments comparing a rapid molecular test with standard of care culture-based testing. Follow-up telephone calls were made at between 2 and 7 days, 1 month, and 3 months after discharge.

Patients at least 18 years old presenting with a chief complaint of abscess, cellulitis, or insect bite and receiving incision and drainage were eligible. Seven hundred seventy-eight people were assessed for eligibility and 252 met eligibility criteria.

Eligibility Criteria:
Inclusion Criteria:

* adults 18 years or older with community onset abscess

Exclusion Criteria:

* previous treatment for same abscess in past 14 days
* postoperative infection
* inability to provide informed consent
The Minnesota Manual Dexterity Test As A Measure Of Hand Function in Multiple Sclerosis

The aim of the study is to report the results of manual dexterity using the Minnesota Manual Dexterity Test in people with Multiple Sclerosis.

Upper limb can be affected even in early stage in people with Multiple Sclerosis (pwMS). Manual dexterity is important to maintain upper limb function and 9-Hole Peg Test (9HPT) is used as gold standard to assess dexterity in pwMS. There are no studies evaluating manual dexterity with the Minnesota Manual Dexterity Test (MMDT) in pwMS. This study aims to:

1. reporting the results of manual dexterity using the Minnesota Manual Dexterity Test and comparing the test results with healthy volunteers,
2. examining the relationship between MMDT and 9HPT, ABILHAND, grip strength, pinch strength, fatigue.

Eligibility Criteria:
Inclusion Criteria:

* (1) age 18-65;
* (2) definitive diagnosis of MS according to McDonald criteria;
* (3) ability to read and write in Turkish.

Exclusion Criteria:

* (1) acute attacks of MS (within 3 months);
* (2) cognitive impairment (Mini Mental test result 24 points and below);
* (3) having spasticity (3 and above according to Modified Ashworth Scale)
* (4) any chronic disease other than MS;
* (5) being addicted to alcohol or drugs,
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML

The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Consistent with the diagnosis of AML
* Age≥18 years at time of consent
* KPS(Karnofsky Performance Scale) ≥70
* Patient's written informed consent
* No steroid therapy within 4 weeks of first DC vaccination
* Stable disease, complete response and partial response(WHO, RECIST)
* Predicted survival≥3 months

Exclusion Criteria:

* Serious dysfunction of vital organs(heart, liver or kidney)
* Received organ transplantation
* Patients with other malignancies or brain metastases
* History of autoimmune diseases
* Pregnant and breast-feeding patient
* Active or chronic infectious diseases
* History of allergy or hypersensitivity to study product excipients
* Currently participating in another clinical trial
* Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks
* Unfit for participating in this clinical trial in investigators' opinions
Comparison of iLTS and LMA Fastrach in a Simulated Airway.

Comparison of time to ventilation based on the chest rising of the Airway Simulator between the iLTS-D and LMA Fastrach

Prior to the study every participant obtained a standardized instruction of each device. In the proposed clinical trial the primary study objective will be to determine whether there is a difference in time to ventilation via endotracheal tube (seconds) for the novel iLTS-D compared to the LMA Fastrach. Time to Ventilation will be defined from when the tip of the extraglottic airway device passed the incisors to the point until confirmation the first chest rise of the high fidelity simulator (Laerdal SimMan). Additionally, two time points before final tracheal placement will evaluated: time to place the EGA and time to ventilate with the EGA after introducing the device into the oral cavity.

Eligibility Criteria:
Inclusion Criteria:

* Medical students
* Present written informed consent of the research participant

Exclusion Criteria:

• inability to consent
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.


Eligibility Criteria:
Inclusion Criteria:

* mild to moderate fungal infection of the toenail as assessed by study doctor
* koh positive \& dermatophyte culture positive at Visit 1
* general good health as assessed by study doctor

Exclusion Criteria:

* severe fungal toenail infection
* prior use of antifungal drugs (wash-out allowed, duration varies on class)
* significant confounding conditions as assessed by study doctor
* pregnancy/lactation
* must forego nail salon procedures during study for at least \~60 weeks